NASDAQ:MDCO - The Medicines Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$39.76 -0.62 (-1.54 %)
(As of 07/18/2018 04:00 PM ET)
Previous Close$40.38
Today's Range$39.28 - $40.86
52-Week Range$24.45 - $43.79
Volume800,900 shs
Average Volume1.13 million shs
Market Capitalization$2.97 billion
P/E Ratio-4.70
Dividend YieldN/A
Beta0.69
The Medicines logoThe Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States. It primarily focuses on developing Inclisiran, a lipid-lowering drug to reduce LDL-cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease or cardiovascular risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Debt-to-Equity Ratio9.70
Current Ratio2.56
Quick Ratio2.52

Price-To-Earnings

Trailing P/E Ratio-4.70
Forward P/E Ratio-11.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.79 million
Price / Sales65.34
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book116.94

Profitability

EPS (Most Recent Fiscal Year)($8.40)
Net Income$-708,370,000.00
Net Margins-1,109.21%
Return on Equity-609.97%
Return on Assets-66.38%

Miscellaneous

Employees170
Outstanding Shares73,610,000
Market Cap$2,967.26

The Truth About Cryptocurrencies

The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) announced its quarterly earnings data on Wednesday, April, 25th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.80) by $0.03. The firm had revenue of $7.71 million for the quarter, compared to the consensus estimate of $9.21 million. The Medicines had a negative net margin of 1,109.21% and a negative return on equity of 609.97%. The business's revenue for the quarter was down 55.8% on a year-over-year basis. During the same period in the prior year, the company posted ($1.05) earnings per share. View The Medicines' Earnings History.

When is The Medicines' next earnings date?

The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for The Medicines.

What price target have analysts set for MDCO?

8 brokerages have issued twelve-month target prices for The Medicines' stock. Their predictions range from $40.00 to $85.00. On average, they anticipate The Medicines' stock price to reach $52.6250 in the next twelve months. This suggests a possible upside of 32.4% from the stock's current price. View Analyst Ratings for The Medicines.

What is the consensus analysts' recommendation for The Medicines?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about The Medicines stock?

Here are some recent quotes from research analysts about The Medicines stock:
  • 1. According to Zacks Investment Research, "The Medicines Co. reported wider-than-expected loss in the first quarter of 2018 with revenues missing estimates. The company’s pipeline boasts a potential blockbuster candidate, inclisiran, being developed for hypercholesterolemia. Moreover, the company implemented a workforce lay-off last year for better alignment of its cost and structure. We are also encouraged by The Medicines Co.’s regular divestiture of non-core products. This would help optimize its capital structure and enhance its liquidity position. However, with Angiomax sales eroding due to presence of generics, the company’s ability to successfully develop and bring in new products to the market is highly important for growth. Any regulatory setback would weigh heavily on the stock. Shares of the company have underperformed the industry in a year’s time." (5/2/2018)
  • 2. Chardan Capital analysts commented, "We found particularly notable: (1) MDCO completing recruitment in just 11 weeks for its 1500-patient ORION-11 pivotal phase III trial of siRNA- based PSCK9 synthesis inhibitor inclisiran (partnered with Alnylam, Buy) and may thus have its first top-line pivotal results in 3Q19, (2) the confirmation commercial scale manufacturing for inclisiran has been achieved, and (3) new inclisiran efficacy data in HoFH to us suggesting efficacy beyond mAb PCSK9 inhibitors. With inclisiran to us having clear momentum towards 2H19E pivotal data and what we expect will be $4.7 billion in 2030E peak sales, we make MDCO a Chardan Top Pick for 2018." (1/24/2018)

Are investors shorting The Medicines?

The Medicines saw a decrease in short interest in June. As of June 15th, there was short interest totalling 19,433,286 shares, a decrease of 6.0% from the May 31st total of 20,683,804 shares. Based on an average daily trading volume, of 882,040 shares, the days-to-cover ratio is presently 22.0 days. Approximately 27.7% of the company's shares are short sold. View The Medicines' Current Options Chain.

Who are some of The Medicines' key competitors?

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:
  • Dr. Fredric N. Eshelman, Exec. Chairman (Age 69)
  • Dr. Clive A. Meanwell, CEO & Director (Age 60)
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 42)
  • Mr. Christopher T. Cox, Chief Corp. Devel. Officer and Exec. VP (Age 53)
  • Mr. William B. O'Connor, Special Advisor to the Chief Exec. Officer (Age 59)

Has The Medicines been receiving favorable news coverage?

Media stories about MDCO stock have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. The Medicines earned a coverage optimism score of 0.04 on Accern's scale. They also gave press coverage about the company an impact score of 45.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of The Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $39.76.

How big of a company is The Medicines?

The Medicines has a market capitalization of $2.97 billion and generates $44.79 million in revenue each year. The company earns $-708,370,000.00 in net income (profit) each year or ($8.40) on an earnings per share basis. The Medicines employs 170 workers across the globe.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (NASDAQ MDCO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  388 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  645
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.